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Background & Aims: There are few population-based studies of the incidence and mortality of 
autoimmune hepatitis. The burden of the disease and how it has changed over time have not been 
fully explored. We conducted a population-based cohort study on the incidence and mortality of 
autoimmune hepatitis in England, 1997–2015. 
Methods: From the Clinical Practice Research Datalink we included 882 patients diagnosed with 
autoimmune hepatitis in England, 1997-2015. The patients were followed through 2015, and we 
calculated the sex- and age- standardised incidence and prevalence of autoimmune hepatitis. We 
examined variation in incidence by sex, age, calendar year, geographical region, and socioeconomic 
status, and incidence rate ratios were calculated with Poisson regression. We calculated all-cause and 
cause-specific mortality. 
Results: The overall standardised incidence rate of autoimmune hepatitis was 2.08 (95% confidence 
interval 1.94-2.22) per 100,000 population per year, higher in women, higher in older age, and 
independent of region and socioeconomic status. From 1997 to 2015 the incidence doubled from 
1.27 (95% confidence interval 0.51-2.02) to 2.56 (95% confidence interval 1.79-3.33) per 100,000 
population per year. The 10-year cumulative all-cause mortality was 31.9% (95% confidence interval 
27.6-36.5), and the 10-year cumulative liver-related mortality, including hepatocellular carcinoma 
was ~ 10.5%. 
Conclusions: This population-based study showed that the incidence of autoimmune hepatitis 
doubled over an eighteen-year period. The incidence was particularly high in older women and was 
similar across all regions of England and independent of socioeconomic status. Patients with 
autoimmune hepatitis had a high mortality.  




Autoimmune hepatitis is a chronic inflammatory liver disease. We studied the English population 
and found that the incidence of autoimmune hepatitis doubled from 1997 to 2015. The resulting 
prevalence was 19 per 100,000 population, i.e. more than 10,000 English people live with AIH in 




Autoimmune hepatitis (AIH) is a female-predominated chronic inflammatory liver disease. The 
aetiology is complex and likely involves interactions between genetic and environmental factors.1,2 
The incidence rate of AIH from various regions of the world ranges from 0.4 to 3.0 per 100,000 
population per year.3-7 Some authors have reported a stable incidence over time,5,8-10 others an 
increasing incidence.3,6,7,11-14 Apart from sex, age, and calendar time, socioeconomic status and 
region of residence may affect the likelihood of being diagnosed with AIH.15,16 Evaluation of the 
variation in AIH incidence over time and place may provide novel insight into the risk factors for 
AIH. For this purpose, population-based studies over long periods are crucial.  
AIH is regarded a treatable disease with effective immunosuppressive medical therapy.17 Even so, 
the reported 10-year cumulative mortality for patients with AIH ranges widely from 4% to 74%. 
Some previous studies concluded that patients with AIH have a higher mortality than the general 
population,5,7,14,18-23 others that patients with AIH have a similar mortality to that of the general 
population.24-29  
We conducted a population-based study of AIH over nearly two decades and across all regions of 
England. We aimed to report the incidence and prevalence of AIH and to determine trends and 
variation in incidence and prevalence by sex, age, calendar year, socioeconomic status, and 
geographical region. We also aimed to report data on mortality, causes of death, and liver 
transplantation for patients with AIH.  
 
MATERIALS AND METHODS 
This is a population-based cohort study of English patients registered with a diagnosis of AIH in 
primary or secondary care between 1997 and 2015. The study is population-based using routine 
healthcare records, and no patient enrolment was involved. The study was approved by the 
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Independent Scientific Advisory Committee for MHRA Database Research, United Kingdom (UK) 
(protocol 17_110RA). 
Data sources 
We extracted data from the Clinical Practice Research Datalink (CPRD) that contains records 
collected from general practice in the UK since 1987.30 These records include sex, dates of birth and 
death, dates of diagnoses defined by Read codes, biochemical tests, and medical prescriptions. Read 
codes are recorded in primary care on the basis of clinical consultations and other resources such as 
hospital discharge notes and discharge diagnoses codes. General practices usually upload data to the 
CPRD on a monthly basis, and a dataset available for research use is concurrently generated on that 
basis. Data quality is assessed by the CPRD against criteria defining patient-level ‘acceptability’ and 
practice-level ‘up-to-standard’ time quality. The CPRD is representative of the overall UK 
population in terms of age, sex, and ethnicity.30 57% of the CPRD practices have consented to 
linkage to other data sources. Since 1997, individual-level data has been linked with data from the 
Hospital Episode Statistics (HES) database. This database includes dates of admission and discharge, 
discharge diagnoses coded according to the International Classification of Diseases 10th edition 
(ICD-10), and procedure codes according to the Office of Population Censuses and Surveys (OPCS) 
classification. The CPRD is also linked to deprivation data defined by quintiles of Index of Multiple 
Deprivation (IMD) at a general practice-level and at a patient-level.31 For the current study we used 
practice-level data because the denominator is the whole of the CPRD population, and access to 
deprivation data for each individual was not permitted. A patient is assigned an IMD score based on 
the average socioeconomic status in the area (each containing around 150 dwellings), in which the 
general practice is situated. Deprivation data in such an area have been found to be a reasonable 
proxy for the level of deprivation of the entire general practice population.32 Since 1998, linkage to 
the Office of National Statistics’ (ONS) death registry has been available. The registry includes 
information on causes of death based on information from death certificates. The causes of death are 
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classified according to the ICD-10, and for each patient one underlying cause of death is defined by 
World Health Organisation standardised criteria.33 
Study population  
We included all permanently registered patients in the CPRD, who were acceptable for research and 
eligible for linkage between 1 April 1997 and 31 December 2015. Cases of AIH were defined by 
CPRD registration of a Read code compatible with AIH or by HES registration of an ICD-10 
diagnosis of AIH between 1 April 1997 and 31 December 2015 (Read codes: J63B.00 autoimmune 
hepatitis, J614000 chronic persistent hepatitis, J614111 autoimmune chronic active hepatitis, or 
J614100 chronic active hepatitis; ICD-10 codes: K73.2 chronic active hepatitis or K75.4 
autoimmune hepatitis). We excluded patients who at any time during follow-up were registered with 
a Read code or an ICD-10 code compatible with alcoholic fibrosis or cirrhosis; viral hepatitis, i.e. 
hepatitis B virus (HBV) or hepatitis C virus (HCV), a positive test result for HBV or HCV, or an 
antiviral treatment for HBV or HCV; or another autoimmune liver disease, i.e. primary sclerosing 
cholangitis (PSC) or primary biliary cholangitis (PBC) (Supplementary Table 1 shows codes for 
exclusion). 
A patient was identified as incident, if 1) the first Read code or ICD code for AIH occurred between 
1 April 1997 and 31 December 2015; 2) the patient had been registered at the same general practice 
for at least 12 months before the diagnosis; and 3) data from that general practice were up-to-
standard. The 12-month time gap after registration ensured that prevalent AIH patients were not 
misclassified as incident ones.34 Patients with an AIH diagnosis date concurrent with a date of death 
were excluded. All other patients with a code for AIH occurring between 1 April 1997 and 31 
December 2015 were considered prevalent AIH cases. Incident AIH patients were classified as 
having or not having cirrhosis at the time of AIH diagnosis. Cirrhosis was defined by registration of 
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a code compatible with cirrhosis or a cirrhosis complication before or within the 6-month period 
after the time of AIH diagnosis (Supplementary Table 2 shows codes defining cirrhosis). 
Death and transplantation 
Information on date of death and underlying cause of death was obtained from the ONS death 
registry. Underlying causes of death were categorised as follows: Liver-related (including cirrhosis 
and cirrhosis complications other than infections and hepatocellular carcinoma [HCC]); HCC; any 
other cancer; infection; cardiovascular disease (including cerebrovascular disease and excluding 
infections); respiratory cause (excluding infections); and other causes of death. Information on liver 
transplantations was obtained from the HES database (Supplementary Table 3 shows codes for 
causes of death and liver transplantation).  
Statistical analyses 
Incidence and prevalence 
The person-time at risk for developing AIH for an individual began after 1 January 1997, when the 
patient had been registered at a general practice for at least 12 months, and after the data were up-to-
standard. The person-time at risk ended at the time of AIH diagnosis, cessation of registration at the 
general practice, the last data collection by the CPRD, death, or end of study on 31 December 2015 
(whichever came first). We calculated the overall incidence rate of AIH as the number of incident 
AIH patients divided by the total person-time at risk. The incidence rates were stratified by sex, age 
group, calendar year, practice-level IMD, and geographical region. We calculated the point 
prevalence of AIH on 31 December 2015 as the number of AIH patients diagnosed before and still 
alive on that date divided by the total number of included CPRD patients who were alive on that 
date. We used direct standardization to standardise incidence and prevalence rates to the European 
standard population’s sex and age distribution in 2013.35 
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We evaluated the time trend in AIH incidence using calendar year as a continuous variable in a 
Poisson regression model fitted to estimate incidence rate ratios of AIH, adjusted for sex, age group, 
IMD, and geographical region. The likelihood ratio test was used to test for interactions between 
calendar year, sex, and age. A Poisson regression model for each sex was then applied to estimate 
adjusted incidence rate ratios. We extracted the percentage-wise change in AIH incidence per 
calendar year. 
Sensitivity analyses 
We repeated calculations of AIH incidence rates including AIH patients with potential overlap 
diagnoses with PSC or PBC, i.e. patients who at any time during follow-up were registered with a 
code compatible with PSC or PBC.  
Mortality and transplantation 
The person-time for risk of death began at the time of AIH diagnosis and ended at death, cessation of 
registration at the general practice, the last data collection by the CPRD, or end of study on 31 
December 2015 (whichever came first). For our cohort of incident AIH patients, we firstly calculated 
the all-cause mortality rate as the number of deaths divided by the total person-time at risk of death, 
and we calculated the 5- and 10-year cumulative mortality based on the Kaplan Meier estimator. The 
rates were stratified by sex, age groups, IMD, and cirrhosis. Secondly, we calculated cause-specific 
mortality rates as the number of deaths from a specific underlying cause divided by the total person-
time at risk of death, and we calculated the 5- and 10-year cumulative mortality from each cause 
based on the cumulative incidence function allowing for the competing risk from other causes of 
death.36 Thirdly, we calculated the 5- and 10-year cumulative incidence of liver transplantation with 
death as a competing risk, and we calculated the 5- and 10- year cumulative incidence of death 





Incidence and prevalence 
We identified 1,008 patients diagnosed with AIH between 1997 and 2015, but 126 were excluded 
from our primary analysis: 31 with a diagnosis of alcoholic liver disease or with a diagnosis date 
concurrent with their date of death (<5 of whom on the basis of the latter); 33 with HBC or HCV; 
and 62 with a diagnosis of PSC or PBC.  
Our final cohort included 882 incident patients with AIH from 10 regions of England; 662 (75.1%) 
were women (median age at diagnosis was 60 years [interquartile range 49-71]). The remaining 220 
(24.9%) were men (median age at diagnosis was 54 years [interquartile range 39-68]). There were no 
missing data on sex, age, geographical region, or IMD. In the 882 patients with AIH, 156 (17.7%) 
had cirrhosis at the time of diagnosis, and a total of 26.0% had developed cirrhosis at the end of 
follow-up. 
For both men and women, the overall incidence rate peaked around 70 years of age (Figure 1). For 
the 1997-2015 period, the standardised incidence rate was 2.08 (95% confidence interval [CI] 1.94-
2.22) per 100,000 population per year with a doubling in incidence from 1997 to 2015 (Table 1 and 
Figure 2). The standardised incidence rate was higher in women than in men. The standardised point 
prevalence on 31 December 2015 was 19.24 (95% CI 18.08-20.41) per 100,000 population.  
The incidence increased between 1997 and 2015 with an average increment per calendar year of 
3.1% (95% CI 1.5 to 4.8) for women and 2.5% (95% CI 0.0-5.3) for men. In the adjusted model the 
incidence was similar regardless of IMD and geographical region (Table 2). We found a three-way 
interaction between sex, age, and calendar year (likelihood ratio test, p=0.003), in that the incidence 
increment over calendar time was mainly apparent in women of older age. 
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The sensitivity analysis including AIH patients with potential overlap diagnoses with PSC or PBC 
comprised 944 patients for an overall standardised incidence rate of 2.23 (95% CI 2.09-2.37) per 
100,000 population per year. The inclusion of these patients did not change the incidence patterns. 
Mortality and transplantation 
Of the 882 patients with AIH, 191 (21.7%) died during a total of 4,216 years of follow-up. The 
mortality rate was particularly high in the first year after AIH diagnosis compared with the rate 
thereafter: 10.00 (95% CI 8.00-12.50) vs. 3.31 (95% CI 2.75-3.98) per 100 patients per year. The 10-
year all-cause cumulative mortality was 31.9% (95% CI 27.6-36.5). The risk of death was higher for 
those diagnosed with AIH in older age, in the deprived, and in those with cirrhosis (Table 3). 
Information on underlying cause of death was missing for less than five persons. Liver-related causes 
of death and death from cancers other than HCC dominated (Figure 3), and the mortality rates were 
especially high in the first year after diagnosis (Table 4).  
Thirteen patients with AIH, of whom five had cirrhosis at the time of diagnosis, had a liver-
transplantation during the follow-up with a 5-year cumulative incidence of transplantation of 1.3% 
(95% CI 0.7-2.4) and a 10-year cumulative incidence of 2.2% (95% CI 1.1-3.7). The 5- and 10-year 
cumulative incidence of death without transplantation was 19.3% (95% CI 16.4-22.4) and 31.4% 
(95% CI 27.0-35.8), respectively.  
 
DISCUSSION 
This population-based study from England showed the highest incidence of AIH among women in 
their seventies. There was no association with region of residence or socioeconomic status. We 
found that the incidence of AIH doubled from 1997 to 2015, resulting in a prevalence of 19 per 
100,000 population. The 10-year all-cause cumulative mortality was 32% with liver-related cause of 
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death being predominant. The mortality rate was particularly high during the first year after 
diagnosis. 
Our study is one of the largest population-based studies on AIH incidence spanning more than a 
decade. Including all regions of England, the study cohort is representative of the entire English 
population.30 The completeness of the recorded diagnoses may be a concern. With the routine 
record-based approach we cannot be certain that every patient with AIH was captured. However, we 
included patients identified in both primary, secondary, and tertiary care. Our incidence and 
prevalence estimates are in accordance with other studies using registry diagnoses for AIH patient 
identification7,14 as well as in accordance with studies using medical notes, biochemistry, and 
histology for patient identification.3,5,6,8-13 This indicates that our case ascertainment is likely to be 
reasonably complete.  
The validity of the routine data diagnoses may also be a concern, as although the validity of 
diagnostic coding in general practice is high,37,38 we did not have liver biopsy data or the data to 
calculate an AIH score to validate the AIH diagnoses39,40. However, our current study did use all 
available data within the routine records combining Read codes we previously identified in primary 
care41 with case ascertainment from secondary and tertiary care using selected ICD-10 codes. In the 
previous study41 the identified Read codes applied to patients discharged with a valid AIH diagnosis 
from tertiary care, i.e. patients who had probable or definite AIH according to the International 
Autoimmune Hepatitis Group simplified score40 or a liver biopsy compatible with AIH, and who had 
been given an AIH diagnosis by a hepatologist consultant. We excluded possibly misclassified cases 
of alcoholic and other autoimmune liver diseases. As for PSC, the ICD-10 code may be unspecific, 
and therefore we might have excluded cholangitis patients with other aetiology than PSC. We will 
stress that the exclusion was primarily based on Read codes registered in the CPRD data, and those 
codes were merely supplemented with ICD-10 codes from the HES. Therefore, it is unlikely that we 
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greatly under-ascertained the prevalence and incidence of AIH. We did not exclude patients with 
non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Although this 
might be a limitation, the awareness of NAFLD and NASH and the completeness of registered 
diagnoses in the CPRD and the HES have probably changed over time. Hence, we were not 
confident to use diagnoses codes for these conditions as exclusion criteria. Furthermore, for the 
patients with AIH any such misdiagnosis is likely to be less of a limitation as these conditions would 
most likely have been ruled out based on presence of the metabolic syndrome, liver histology, and/or 
autoantibody profile during the diagnostic workup for AIH. Therefore, it is also unlikely that we 
greatly over-ascertained the prevalence and incidence of AIH. With the exclusion of patients with 
diagnoses of the other chronic liver diseases that may have higher associated mortality, our mortality 
estimates are too unlikely to have been overestimated.  
The overall standardised incidence rate of 2.1 per 100,000 population per year in our study is similar 
to the incidence rates reported in our previous Danish study14, a New Zealand study,8 and a recent 
Icelandic study,6 all population-based. We confirmed the well-known female predominance of AIH. 
In line with previous studies from the UK9,42-44 and studies from others parts of the world3,6-
8,10,11,13,14,19,45-48 we found an incidence peak in older age. We could not confirm a peak in younger 
age that was found in some of the studies,10,14,19,48 and that might relate to risk factor exposures in 
younger age in some countries. Yet, we cannot rule out that our definition of incident cases may have 
biased against detecting cases in the younger subset of the CPRD population, who are more mobile 
and less likely to be permanently registered with the same CPRD general practice.  
In the patients with AIH, we found a lower proportion of cirrhosis than in most other studies. 
However, these studies were from tertiary centres that might have been biased by only including 
more severe cases of AIH.10,11,29,47,49 Our study, on the other hand, also includes patients from 
primary and secondary care and might therefore be able to identify patients diagnosed at an earlier 
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stage before developing cirrhosis. Two population-based studies found an even lower proportion of 
cirrhosis at the time of diagnosis than we did,6,13 and compared with the Danish study, we found a 
similar final proportion of cirrhosis.14  
In line with a population-based case-control study,16 we found no association between 
socioeconomic status and the incidence of AIH. One review found an association between 
socioeconomic status (high human development index) on a country level and high AIH incidence,15 
but such a finding does not necessarily reflect an association on an individual level.50 We did not 
have access to patient-level socioeconomic status, either, but deprivation data was obtained from 
smaller areas with presumably smaller variation compared with variation within whole countries.  
With a doubling of AIH incidence from 1997 to 2015, we confirmed the findings of our previous 
Danish study14 and other population-based studies.6,7,13 Some authors have reported a stable 
incidence over time,5,8-10 yet others an increasing incidence, but arguing that the increase was a result 
of increased diagnostic activity.3,11,12 The current study and a previous English study51 show higher 
incidence rates than older UK studies from the 1970s and 1990s.9,44 This may partly be explained by 
an increased diagnostic ascertainment over time,3,11,12 but in preliminary data analyses, 2005-2015, 
there was an overall decline in the testing rates of liver function tests within the whole CPRD dataset 
(personal communication, Dr Lu Ban). Moreover, if increased diagnostic ascertainment was the only 
explanation, the incidence would eventually plateau, as the clinical diagnosis rate approached the 
underlying, true population rate. Similar incidence time trends were reported for many other 
autoimmune diseases, such as PSC, rheumatoid arthritis, inflammatory bowel disease, and 
diabetes,52,53 and therefore there might be an increasing overall awareness of autoimmune diseases. 
However, in contrast to this, the reported incidence over time of yet other autoimmune diseases such 
as polymyalgia rheumatica has remained relatively stable over time,54 for coeliac disease it has 
increased and then stabilized,55 and for dermatitis herpetiformis it has declined.56 We cannot exclude 
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the possibility that our results partly reflect an increasing incidence of AIH diagnoses rather than an 
increasing incidence of the disease AIH, and any such concern would apply to the majority of 
reported disease incidence estimates. Our study, the Danish,14 and the Dutch study13 were large and 
spanned a long period with sustained incidence increases, and we believe that more people actually 
developed AIH. Genetic susceptibility to AIH is unlikely to have varied over time to an extent that 
would have caused a doubling in incidence over 18 years. Therefore, environmental factors may be 
the more likely explanation, with risk factors either accumulating over time, or protective factors 
being lost.57 A recent population-based study, 2006-2015, from Iceland suggested that drug-induced 
AIH, mainly due to biological drugs, could explain the incidence increase.6 In the original AIH 
diagnostic score, revised in 1999,39 the use of hepatotoxic drugs would count against a diagnosis of 
AIH, whereas in the simplified AIH score, 2008,40 that criterion was not included. For our study 
period, both scoring systems could have been used, and an increasing use of hepatotoxic drugs such 
as biological drugs may have contributed to our findings.  
 In line with the Danish study14 and a recent study from Finland7 the incidence increase was more 
distinct in women than in men, particularly in older women. These findings might be attributable to a 
lower threshold for autoimmune trigger mechanisms in women due to female hormones, whereas the 
interpretation of the interaction with older age remains unclear. Future studies of risk factors for AIH 
will need to make separate analyses for men and women and for the young and the old.  
In line with most previous studies,5,7,14,18-23 our findings support the notion that patients with AIH 
have a high mortality. We were unable to include details on hospital care or medical management of 
the patients, as CPRD data, even with linkage with HES, cannot reliably determine such details. We 
found a 10-year mortality risk of 32% that was higher than in the other studies, and this is likely to 
be partially explained by a higher median age of our study cohort. Lower age undoubtedly also 
contributed to the findings of mortality risks as low as 4% from other studies, but the selection of 
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patients with AIH in those studies could also be of significance: one study solely included patients 
with type 1 AIH;26 other studies were single-centre studies and may consequently have included a 
selected group of patients with a favourable prognosis;24,25,29 and two studies included Japanese 
patients, who often present with less severe disease.27,28 Furthermore, one of the Japanese studies28 
evaluated survival only in patients who were followed more than 12 months after AIH diagnosis. 
These patients would have had to survive 12 months after diagnosis to be included in the analysis, 
and this would have biased the survival curve upwardly.58 Likewise, one English study29 only 
included patients who had a diagnostic liver biopsy and a further biopsy while on medical treatment 
for AIH, and this could also have biased the survival curve.58 Another English study included 245 
patients who fulfilled the diagnostic criteria for AIH and found a higher mortality than in the general 
population.23 The results from our current larger population-based study suggest that AIH in England 
is still a dangerous disease, and in line with other studies,5,14,18,19,21,22,29 the mortality was higher in 
those diagnosed in older age and in those with cirrhosis The excess mortality rate in those with a 
lower affluence corresponds to the findings from a study on deprivation and associated mortality in 
England and Wales.59  
One single centre study on mortality in patients with AIH26,27 found that liver-related death 
accounted for as little as 0%,60 others found it to account for as much as 50%,26,27 but these studies 
were small. Larger population-based studies with long-term follow-up5,7,14,21,22 found a frequency of 
liver-related death, including HCC, of 32-49% and death from other cancers of 15-25%; and our 
findings are comparable to theirs. Extending the results from the other studies, we quantified the 
cause-specific cumulative risks of death in the patients with AIH, and we found a high long-term 
mortality risk that was mainly liver- and cancer-related. The all-cause mortality rate and the rate 
from liver-related causes and other cancers were particularly high in the first year following AIH 
diagnosis. The current results substantiate the finding of a pronounced excess mortality in the first 
year after diagnosis from our previous Danish study.14 In line with some,7,14,20,21 but not all,5,22 
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population-based studies, only 1.5% of our English study cohort had a liver transplantation. This 
proportion is slightly higher than expected, based on the 2017/2018 National Health Service annual 
report on liver transplantations in the UK,61 and even more patients with AIH might benefit from 
transplantation.  
In conclusion, we found a high incidence of AIH in England, particularly in women in their 
seventies. The incidence of AIH in England is increasing, and studies to identify risk factors are 
increasingly important. We found a high mortality in English patients with AIH, and the mortality 
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Figure 1. Sex- and age-specific incidence rates of autoimmune hepatitis in England, 1997-2015.  
 
Figure 2. Sex and age- standardised incidence rates (SIR) of autoimmune hepatitis in England 
for each calendar year 1997-2015. Incidence rates were standardised with the direct method to the 
European standard population’s sex and age distribution 2013. 
 
Figure 3. Stacked curve of cause-specific cumulative incidence of death following autoimmune 
hepatitis diagnosis. Estimates were based on the competing risk estimator of cumulative incidence 
of death with other causes of death as competing risks.  
 
 
 
 
 
 
 
 
 
 
 
